WO2017079566A1

WO2017079566A1 - Caspase inhibitors for use in the treatment of liver cancer

Info

Publication number: WO2017079566A1
Application number: PCT/US2016/060541
Authority: WO
Inventors: Alfred P. Spada
Original assignee: Conatus Pharmaceuticals, Inc.
Priority date: 2015-11-05
Filing date: 2016-11-04
Publication date: 2017-05-11

Abstract

Provided herein are methods and compositions for treatment of liver cancer by administering a caspase inhibitor in combination with chemotherapeutic agents for liver cancer.

Description

CASPASE INHIBITORS FOR USE IN THE TREATMENT OF LIVER CANCER

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of the priority of U.S. Provisional Application No. 62/251,560, filed November 5, 2015, the disclosure of which is incorporated herein by reference in its entirety.

1. FIELD

[0001] Provided herein are methods of treating liver cancer by administering a caspase inhibitor and a second therapeutic agent.

2. BACKGROUND

[0002] Liver cancer is the second most common cancer related cause of death in the world. Additionally, the incidence of liver cancer is increasing at a time when the incidence of other major cancers are decreasing. Bruix, J. et al. Liver cancer: Approaching a personalized care. J. Hepatology 2015; 62: S144-S156. It is estimated that approximately 35,700 will be diagnosed with liver cancer and approximately 25,600 will die of the disease in the United States in 2015. {American Cancer Society Liver Cancer.

www.cancer.org/acs/groups/cid/documents/webcontent/003114-pdf.) As such, liver cancer a disease that affects a large and growing number of people in the United States. Liver cancer is associated with a high degree of morbidity and mortality and current treatment options are limited. Therefore the development of new more effective therapies for the treatment of liver cancer are urgently needed.

3. SUMMARY

[0003] In one aspect, provided herein are methods for treating liver cancer by a caspase inhibitor in combination with a second agent. Caspase inhibitors as known to and understood by one of skill in the art are contemplated herein. In one aspect the second agent can be a chemotherapeutic agent. Chemotherapeutic agents as known to and understood by one of skill in the art are contemplated herein. Exemplary compounds and agents for use in the methods are described elsewhere herein. Also provided are pharmaceutical compositions for use in the methods.

[0004] In certain embodiments, the methods provided herein include treatment of liver cancer resulting from Nonalcoholic Fatty Liver Disease (NAFLD). NAFLD is a disease in which fat is deposited in the liver and can cause liver injury and metabolic changes that can lead to liver cancer. In one embodiment, the NAFLD is nonalcoholic steatohepatitis (NASH). NASH is a disease in which fat deposited in the liver causes inflammation and damage to the liver. This can lead to cirrhosis of the liver. Liver cancer is known to develop in patients with NASH with or without cirrhosis.

[0005] In certain embodiments, the methods provided herein include treatment of liver cancer resulting from metabolic syndrome.

[0006] In certain embodiments, the methods provided herein include treatment of liver cancer resulting from viral disease. In one embodiment, the viral disease is hepatitis C (HCV). In another embodiment the viral disease is hepatitis B (HBV).

[0007] In certain embodiments, the methods provided herein include treatment of liver cancer resulting from alcoholic liver disease. In one embodiment, the alcoholic liver disease is alcoholic hepatitis. In another embodiment the alcoholic liver disease is alcoholic liver cirrhosis.

[0008] In certain embodiments, the methods provided herein include treatment of liver cancer resulting from cryptogenic liver cirrhosis where the cause of liver cirrhosis is not known.

[0009] In certain embodiments, the methods provided herein include treatment of liver cancer resulting from chronic cholestatic liver disease. In one embodiment, the chronic cholestatic liver disease is primary biliary cirrhosis (PBC). In another embodiment the chronic cholestatic liver disease is primary sclerosing cholangitis (PSC).

[0010] In certain embodiments, the methods provided herein include treatment of liver cancer resulting parasitic infection. In one embodiment, the parasitic infection causes schistosomiasis.

[0011] In certain embodiments, the methods provided herein include treatment of liver cancer resulting from ingestion of food-borne toxins. In one embodiment, the food-borne toxin is mycotoxin aflatoxin B 1.

[0012] In certain embodiments, the methods provided herein include treatment of liver cancer resulting from inflammatory bowel disease. In one embodiment, inflammatory bowel disease is ulcerative colitis.

[0013] In one embodiment, the liver cancer is hepatocellular carcinoma.

[0014] In one embodiment, the liver cancer is cholangiocarcinoma. [0015] In certain embodiments, provided are methods for treatment of patients who have failed to achieve results, for example, reduced tumor size, with conventional therapy used in the treatment of liver cancer.

[0016] In certain embodiments, provided are methods for treatment of patients who are refractory to therapy used in the treatment of liver cancer.

[0017] In certain embodiments, provided are methods for treatment of patients who have failed to achieve desired clinical benefit, for example, reduced tumor size, with conventional therapy used in the treatment of liver cancer.

[0018] In certain embodiments, the methods of treating with a caspase inhibitor and a chemotherapeutic agent provided herein further comprise surgical resection. In certain embodiments, the methods further comprise administration of a third anti-cancer agent.

[0019] In one embodiment, the methods provided herein improve survival in liver cancer patients.

[0020] Also provided are caspase inhibitors for use in the methods provided herein. In one embodiment, the caspase inhibitor compound for use in the methods provided herein is selected from:

VX-765, belnacasan or a pharmaceutically acceptable derivative thereof. In one embodiment, the pharmaceutically acceptable derivative is a pharmaceutically acceptable salt.

[0021] In one embodiment, the caspase inhibitor for use in the methods provided herein is

IDN7314

or a pharmaceutically acceptable derivative thereof. In one embodiment, the pharmaceutically acceptable derivative is a pharmaceutically acceptable salt.

[0022] In some embodiments, two or more caspase inhibitors are used sequentially or simultaneously in the methods provided herein.

[0023] Also provided are pharmaceutical compositions containing therapeutically effective amounts of the compounds provided herein and a pharmaceutically acceptable carrier, wherein the pharmaceutical compositions are useful in the treatment, or amelioration of one or more of the symptoms of liver cancer.

[0024] Further provided is an article of manufacture containing a packaging material, the compounds or pharmaceutically acceptable derivatives thereof provided herein, which is used for treatment, prevention or amelioration of one or more symptoms associated with liver cancer, and a label that indicates that compounds or pharmaceutically acceptable derivatives thereof are used for the treatment or amelioration of one or more symptoms of liver cancer. In the one embodiment, the article of manufacture comprises a packaging material, compounds: IDN-7314 and a chemotherapeutic agent as described herein, and a label that indicates that the compounds are used for the treatment or amelioration of one or more symptoms of liver cancer.

4. BRIEF DESCRIPTION OF FIGURES

[0025] Figure 1 demonstrates that caspase inhibitor IDN-7314 sensitizes colon cancer cells to chemotherapy -induced necrotic cell death.

[0026] Figure 2 demonstrates the effect of combinatory treatment with IDN-7314 and 5- fluorouracil (5-FU) on the size of tumor in HT29 xenografts.

[0027] Figure 3 illustrates tumor regression in HT29 xenografts treated with IDN-7314 (referred to as IDN in the figure) and 5-fluorouracil (referred to as 5-FU in the figure). 5. DETAILED DESCRIPTION OF THE EMBODIMENTS

[0028] The methods, compounds, pharmaceutical compositions and articles of manufacture provided herein are characterized by a variety of component ingredients, steps of preparation, and steps of execution and associated biophysical, physical, biochemical or chemical parameters. As would be apparent to those of skill in the art, the methods provided herein can include any and all permutations and combinations of the compounds, compositions, articles of manufacture and associated ingredients, steps and/or parameters as described below.

5.1. Definitions

[0029] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art. All patents, applications, published applications and other publications are incorporated by reference in their entirety. In the event that there are a plurality of definitions for a term herein, those in this section prevail unless stated otherwise.

[0030] The singular forms "a," "an," and "the" include plural references, unless the context clearly dictates otherwise.

[0031] As used herein "subject" is an animal, such as a mammal, including human, such as a patient.

[0032] As used herein, biological activity refers to the in vitro or in vivo activities of a compound or physiological responses that result upon in vivo administration of a compound, composition or other mixture. Biological activity, thus, encompasses therapeutic effects and pharmacokinetic behavior of such compounds, compositions and mixtures. Biological activities can be observed in in vitro and in vitro systems designed to test for such activities.

[0033] As used herein, "chemotherapeutic agent" is an agent that shows activity against liver cancer in a clinical study or assay designed to test for such activity. Such activity can be observed in in vitro and/or in vitro systems. Exemplary assays are described by Sharma, S. et al. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nature Reviews Cancer 2010; 10:241-253, Vecsey-Semjen, B. et al. Novel colon cell lines leading to better understanding of the diversity of respective primary cancers. Nature Oncogene 2002; 21 : 4646-4662. Evaluation of activity in in vivo models of liver cancer are described by Caviglia, J. et al. Mouse models of liver cancer. Methods Mol. Biol. 2015; 1267: 165-183, He, L. et al. Mouse models of liver cancer: Progress and recommendations. Oncotarget 2015; 6: 23306- 22, De Minicis, S. et al. Liver carcinogenesis: Rodent models of hepatocellular carcinoma and cholangiocarcinoma. Dig Liver Dis. 2013; 45:450-459, Li, Y. et al. Hepatocellular carcinoma: Insight from animal models. Nat. Rev. Gastroenterol. Hepatol. 2011; 9: 32-43 and Heindryckx, F. et al. Experimental mouse models for hepatocellular carcinoma research. Int. J. Exp. Path. 2009; 90: 367-386.

[0034] As used herein, "microparticles" are subcellular fragments of varying sizes.

Microparticles are also known in the art as microvesicles, extracellular microvesicles, extracellular vesicles, apoptotic bodies and exosomes.

[0035] As used herein, pharmaceutically acceptable derivatives of a compound include salts, esters, acetals, ketals, orthoesters, hemiacetals, hemiketals, acids, bases, solvates, hydrates or prodrugs thereof. Such derivatives may be readily prepared by those of skill in this art using known methods for such derivatization. The compounds produced may be administered to animals or humans without substantial toxic effects and either are pharmaceutically active or are prodrugs. Pharmaceutically acceptable salts include, but are not limited to, amine salts, such as but not limited to Ν,Ν'-dibenzylethylenediamine, chloroprocaine, choline, ammonia,

diethanolamine and other hydroxyalkylamines, ethylenediamine, N-methylglucamine, procaine, N-benzylphenethylamine, 1 -para-chlorobenzyl-2-pyrrolidin- 1 '-ylmethylbenzimidazole, diethylamine and other alkylamines, piperazine and tris(hydroxymethyl)aminomethane; alkali metal salts, such as but not limited to lithium, potassium and sodium; alkali earth metal salts, such as but not limited to barium, calcium and magnesium; transition metal salts, such as but not limited to zinc; and inorganic salts, such as but not limited to, sodium hydrogen phosphate and disodium phosphate; and also including, but not limited to, salts of mineral acids, such as but not limited to hydrochlorides and sulfates; and salts of organic acids, such as but not limited to acetates, lactates, malates, tartrates, citrates, ascorbates, succinates, butyrates, valerates, mesylates, and fumarates. Pharmaceutically acceptable esters include, but are not limited to, alkyl, alkenyl, alkynyl, aryl, aralkyl, and cycloalkyl esters of acidic groups, including, but not limited to, carboxylic acids, phosphoric acids, phosphinic acids, sulfonic acids, sulfinic acids and boronic acids. Pharmaceutically acceptable solvates and hydrates are complexes of a compound with one or more solvent or water molecules, or 1 to about 100, or 1 to about 10, or one to about 2, 3 or 4, solvent or water molecules. [0036] As used herein, treatment means any manner in which one or more of the symptoms of a disease or disorder are ameliorated or otherwise beneficially altered. Treatment also encompasses any pharmaceutical use of the compositions herein, such as use for treating liver cancer.

[0037] As used herein, amelioration of the symptoms of a particular disorder by

administration of a particular compound or pharmaceutical composition refers to any lessening, whether permanent or temporary, lasting or transient that can be attributed to or associated with administration of the composition.

[0038] As used herein, and unless otherwise indicated, the terms "manage," "managing" and "management" encompass preventing the recurrence of the specified disease or disorder in a patient who has already suffered from the disease or disorder, and/or lengthening the time that a patient who has suffered from the disease or disorder remains in remission. The terms encompass modulating the threshold, development and/or duration of the disease or disorder, or changing the way that a patient responds to the disease or disorder.

[0039] It is to be understood that the compounds provided herein may contain chiral centers. Such chiral centers may be of either the (R) or (S) configuration, or may be a mixture thereof. Thus, the compounds provided herein may be enantiomerically pure, or be stereoisomeric or diastereomeric mixtures. As such, one of skill in the art will recognize that administration of a compound in its (R) form is equivalent, for compounds that undergo epimerization in vivo, to administration of the compound in its (S) form.

[0040] As used herein, substantially pure means sufficiently homogeneous to appear free of readily detectable impurities as determined by standard methods of analysis, such as thin layer chromatography (TLC), gel electrophoresis, high performance liquid chromatography (HPLC) and mass spectrometry (MS), used by those of skill in the art to assess such purity, or sufficiently pure such that further purification would not detectably alter the physical and chemical properties, such as enzymatic and biological activities, of the substance. Methods for purification of the compounds to produce substantially chemically pure compounds are known to those of skill in the art. A substantially chemically pure compound may, however, be a mixture of stereoisomers. In such instances, further purification might increase the specific activity of the compound. The instant disclosure is meant to include all such possible isomers, as well as, their racemic and optically pure forms. Optically active (+) and (-), (R)- and (S)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, such as reverse phase HPLC. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included.

[0041] In certain embodiments, the compound used in the methods provided herein is "stereochemically pure." A stereochemically pure compound or has a level of stereochemical purity that would be recognized as "pure" by those of skill in the art. In certain embodiments, "stereochemically pure" designates a compound that is substantially free of alternate isomers. In particular embodiments, the compound is 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% free of other isomers.

[0042] As used herein, "therapy for liver cancer" or "conventional therapy for liver cancer" refers to a treatment with radiation or any medication known, available in the market and being developed for the treatment of liver cancer. For example, therapy of liver cancer refers to treatment of the patient with drugs available in the market for the treatment of liver cancer. Several exemplary drugs are described elsewhere herein.

[0043] As used herein, "treatment" means any manner in which one or more of the symptoms of a disease or disorder are ameliorated or otherwise beneficially altered. Treatment also encompasses any pharmaceutical use of the compositions herein, such as use for treating of liver cancer.

[0044] As used herein, "mitigate" means the reduction or elimination of symptoms. Mitigate also means the reduction of severity or the delayed progression of disease or being otherwise beneficially altered.

[0045] As used herein, amelioration of the symptoms of a particular disorder by

[0046] As used herein, "patients who have failed therapy" refers to the patient population described elsewhere herein and includes patients that have previously been treated for liver cancer with any of the drugs or procedures currently available in the market and either did not respond to the therapy (used synonymously herein with "failed therapy"), become refractory to therapy, could not tolerate the therapy or for whom the therapy was medically contraindicated.

[0047] As used herein, the term "in combination" refers to the use of more than one therapies (e.g., a caspase inhibitor and other agents). The use of the term "in combination" does not restrict the order in which therapies (e.g., a caspase inhibitor and other agents) are administered to a subject with a disorder. A first therapy (e.g., a caspase inhibitor and other agents) can be administered prior to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before), concomitantly with, or subsequent to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) the administration of other therapy (e.g., a caspase inhibitor and other agents) to a subject with a disorder.

[0048] As used herein, the term "synergistic" refers to a combination of a caspase inhibitor with another agent, which is more effective than the additive effects of the administration of the two compounds as monotherapies. A synergistic effect of a combination of therapies (e.g., a caspase inhibitor and another agent) permits the use of lower dosages of one or more of the therapies and/or less frequent administration of the therapies to a subject with a disorder. The ability to utilize lower dosages of a therapy (e.g., a caspase inhibitor and another agent) and/or to administer the therapy less frequently reduces the toxicity associated with the administration of the therapy to a subject without reducing the efficacy of the therapy in the prevention or treatment of a disorder. In addition, a synergistic effect can result in improved efficacy of agents in the prevention or treatment of a disorder. Finally, a synergistic effect of a combination of therapies (e.g., a caspase inhibitor and another agent) may avoid or reduce adverse or unwanted side effects associated with the use of either therapy alone.

5.2. Cancer

[0049] All cancerous tumors arise due to various defects in the mechanisms that control the rate of cell growth. In healthy individuals, the rate of cell growth is balanced with the rate of cell removal in any given tissue. In cancers, the rate of cell growth exceeds the rate of normal cell loss, resulting in the formation of tumors. The biological mechanisms leading to these imbalances are varied and complex. However, certain hallmarks of cancer that are generally accepted to be critical in the development and progression of cancer as described in Hanahan, D. The hallmarks of cancer. Cell 2000; 100: 57-70 and Hanahan, D et al. Hallmarks of cancer: The next generation. Cell 2011; 144: 646-674. One of these hallmarks is believed to be the ability of cancer cells to evade a process of cell death known as apoptosis. Apoptosis is a genetically programmed form of cell death that is critical to normal tissue function and maintain tissue size. The foundation of all non-surgical treatments for cancer rely on the direct killing cancer cells without damaging healthy tissue. In cancer, it is believed that cancer cells develop a resistance to apoptosis and therefore are less readily removed and evade the normal physiological processes to remove these cells. As a consequence, the tumor can grow and spread more readily in an environment wherein apoptosis is curtailed as described in Vermeulen, K. et al. Apoptosis: mechanisms and relevance in cancer Ann. Hematol. 2005; 84: 627-639, Delbridge, A. et al. The role of the apoptotic machinery in tumor suppression. Cold Spring Harbor Perspectives in Biology 2012; 4: a008789, Fernald, K. et al. Evading apoptosis in cancer. Trends in Cell Biol. 1013; 12: 620-633, Ghavami, S. et al. Apoptosis and cancer: mutations within caspase genes. J. Med. Genetics 2009; 46: 497-510, Cai, X. et al. Overcoming Fas-mediated apoptosis accelerated Helicobacter-induced gastric cancer in mice. Cancer Res. 2005; 65: 10912-20, Mohammad, R. Broad targeting of resistance to apoptosis in cancer. Semin. Cancer Biol. 2015;

http://dx.doi.Org/10.1016/j .semcancer.2015.03.001. Therefore, strategies to develop new drugs to treat cancer have focused on multiple methods to increase apoptosis of tumor tissue as described in Khan, K. et al. Cancer therapeutics: Targeting the apoptotic pathway. Oncology Hematology 2013; 90: 200-219, Reed, J. Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms. Nature Clinical Practice Oncology 2006; 3 : 388-398, Lessene, G. et al. BCL-2 family antagonists for cancer therapy. Nature Reviews Drug Discovery 2008; 7:989-1000, Kang, M. et al. Bcl2- inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy Clin. Cancer Res. 2009; 15: 1126-1132, Mannhold, R. et al. IAP antagonists: promising candidates for cancer therapy. Drug Discovery Today 2010; 15: 210-19, Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumors. Nature 2005; 435: 677-681, Tse, C. et al. ABT-263 : a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008; 68:3241-3248, Souers, A. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nature Medicine 2013; 19: 202-8, Mertens, J. et al. Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. Cancer Res. 2012; 73 : 897-907, Rizvi, S et al. J. Biol. Chem. 2014;

289:22835-22849 and Fulda, S. Molecular pathways: targeting inhibitor of apoptosis protein in cancer-from molecular mechanism to therapeutic application. Clin. Cancer Res. 2014; 20:289- 295.

[0050] However, apoptosis and caspase activity is quite commonly elevated, not reduced, in human cancers. In addition, elevated apoptosis has been shown to correlate with the severity and stage and aggressiveness of human cancers as described in Hu Q., et al. Elevated cleaved caspase 3 is associated with shortened overall survival in several cancer types. Int. J. Clin. Exp. Pathol. 2014; 7: 5057-5070, Persad R. et al. Overexpression of caspase-3 in hepatocellular carcinomas. Modern Pathology 2004; 17: 861-867, Hikita, H. et al. Bak deficiency inhibits liver

carcinogenesis: a causal link between apoptosis and carcinogenesis. J. Hepatology 2012; 57: 92- 100, Koelink, P. et al. Circulating cell death products predict clinical outcome of colorectal cancer patients. BMC Cancer 2009; 8: 88. doi: 10.1186/1471-2407-9-88, Ueno, T. et al.

Measurement of an apoptotic product in the sera of breast cancer patients. Eur. J. Cancer 2003; 39: 769-774, Roth, C. et al Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression. BMC Cancer. 2011; 11 : 4 doi: 10.1186/1471-2407-l l-4, Engels C. et al. The prognostic value of apoptotic and proliferative markers in breast cancer. Breast Cancer Res. Treat. 2013; 142:323-339, Ulukaya, E. et al. The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict survival. Lung Cancer 2007;56:399-404, Oyama, K. et al. Serum cytokeratin 18 as a biomarker for gastric cancer. Clin. Exp. Med. 2013; 4: 289-295, Greystoke, A. et al. Multi-level evidence that circulating CK18 is a biomarker of tumor burden in colorectal cancer and Morris, K. et al. Circulating biomarkers in hepatocellular carcinoma. Cancer Chemother. Pharmacol. 2014;74:323-32.

[0051] Cancer cells that undergo apoptosis release small particles into the surrounding tissue and circulation known collectively as microparticles. These small particles released from cancer cells are known to contain substances that are capable of transforming healthy tissue into tumor tissue. Additionally, these particles have the ability to stimulate the production of new blood vessels, a process known as angiogenesis, which facilitates tumor growth. Hence, these particles have been demonstrated to have pro-turn origenic properties that can continue the progression of cancer as described in Ogorevc, E. et al. The role of extracellular vesicles in phenotypic cancer transformation. Radiol. Oncol. 2013; 47: 197-205, Antonyak, M. et al. Cancer cell-derived microparticles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells. WAS 2011; 108: 4852-4857, Haga, H. et al. Tumour cell-derived extracellular vesicles interact with mesenchymal stem cells to modulate the microenvironment and enhance cholangiocarcinoma growth. Journal of Extracellular Vesicles 2015; 4: 24900

doi.org/10.3402/jev.v4.24900, D'Asti, E. et al. Oncogenic extracellular vesicles in brain tumor progression. Front.in Physol. 2012; 3 : Article 294, Kogure, T. et al. Intercellular nanovesicle- mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology 2011; 54: 1237-1248, Vader, P et al. Extracellular vesicles: emerging targets for cancer therapy. Trends in Molecular Med. 2014; 20: 385-393, Garcia-Olmo D. et al. Cell-free nucleic acids circulating in the plasma of colorectal cancer patients induce oncogenic transformation of susceptible cultured cells. Cancer Res. 2010; 70: 560-567, Zhang, H. et al Exosomes: a novel pathway of local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions. Am. J. Pathol. 2012; 184: 28-41, Martins, V et al Tumor-cell-derived microvesicles as carriers of molecular information in cancer. Curr. Opin. Oncol. 2013; 1 : 66-75, McDaniel, K. et al. Functional role of microvesicles in gastrointestinal malignancies. Ann. Transl. Med. 2013; 1 :4 doi: 10.3978/j .issn.2305- 5839.2012.10.01, and Clancy J et al. Regulated delivery of molecular cargo to invasive tumour- derievd microvesicles. Nat. Commun. 2015; 6:6919 doi: 10.1038/ncomms7919. Reducing the production of tumor derived microparticles from cells reduces this drive and can facilitate tumor clearance in combination therapy.

[0052] Caspase inhibitors described herein have been shown to reduce the production of microparticles and apoptosis in models of liver disease. For example as described by Verma, V. et al. Alcohol stimulates macrophage activation through caspase dependent hepatocyte derived release of CD40L containing extracellular vesicles. Hepatology 2014; 60: 857A, Eguchi, A. et al. Emricasan, a pan caspase inhibitor, improves survival and portal hypertension in a murine model of long-term common bile duct ligation. Hepatology 2015; 62: 952 A and Hoglen, N. et al. Characterization of IDN-6556 (3 - { 2-(2-tert-butylphenylaminooxalyl)-amino] -propiony lamino } - 4-oxo-5-(2,3,5,6-tetrafluoropenoxy)-pentanoic acid): a liver-targeted caspase inhibitor. J. Pharm. Exp. Therapeutics. 2003; 309: 634-640. [0053] Caspases may also regulate multiple processes in addition to apoptosis as described in Connolly, P. et al. New roles for old enzymes: killer caspases as the engine of cell behavior changes. Frontiers in Physiology 2014; 5: doi.10.3389/fphys.2014.00149. Inhibition of caspases may activate other forms of cell death that may facilitate the killing of tumor cells as described in Jain, M. et al. Interconnections between apoptotic, autophagic and necrotic pathways:

implications for cancer therapy development. J. Cell. Mol. Med. 2013; 17: 12-29.

5.3. Caspase inhibitor compounds

[0054] Several caspase inhibitors that can be used in the methods provided herein have been reported in the literature. Certain exemplary caspase inhibitors for use in the methods are described by Linton in Current Topics in Medicinal Chemistry, 2005; 5: 1-20; and Linton et al. in J. Med. Chem., 2005;48: 6779-6782, U.S. patent no. 7,351,702; 7,410,956; 7,443,790;

7,553,852; 7,652, 153; 7,612,091; 7,807,659; 7,857,712; 7,960,415; 8,071,618; 7,074,782;

7,053,057; 6,689,784; 6,632,962; 6,559,304; 6,201, 118; 6,800,619, 6, 197,750; 6,544,951;

6,790,989; 7,053,056; 7,183,260; 7,692,038 and International application nos. WO 2006/017295; WO 2005/021516; WO 04/002961; WO 02/085899; WO 02/094263 and WO 01/094351. The contents of these references are hereby incorporated by reference in their entireties.

[0055] In one embodiment, the caspase inhibitor for use in the methods provided herein is selected from

[0056] In one embodiment, the caspase inhibitor for use in the methods provided herein is

IDN-7314

[0057] In some embodiments, more than one caspase inhibitor can be used sequentially or simultaneously in the methods provided herein.

[0058] In certain embodiments, the compounds described herein have efficacy in models of liver cancer following oral administration of from 0.001 - 1000 mg/Kg. In certain embodiments, the compounds described herein have efficacy in models of liver cancer following oral administration of from 0.01 - 100 mg/Kg.

5.4. Chemotherapeutic agents

[0059] Chemotherapeutic agents that can be used in the methods provided herein have been reported in the literature. Certain exemplary chemotherapeutic agents for use in the methods are described by Schlachterman, A et al. Current and future treatments for hepatocellular carcinoma. World J. Gasteroenterol. 2015; 21 :8478-8491, Bruix, J. et al. Liver cancer: Approaching a personalized care. J. Hepatology 2015; 62: S144-S156. American Cancer Society Monograph: Liver Cancer, http://www.cancer.org/acs/groups/cid/documents/webcontent/003114-pdf.pdf, incorporated by reference herein in their entirety. In certain embodiments, the chemotherapeutic agent is selected from 5-fluorouracil (5-FU); doxorubicin (Adriamycin); cisplatin; sorafenib (Nexavar®); Doxorubicin; Cisplatin; mitomycin C, floxuridine (FUDR), Sunitinib; ramucirumab (Cyramza®); regorafenib (Stivagra®); Lenvatinib; Brivanib; Tivantinib; Linifanib; Foretinib; Refametinib; Selumetinib; Erlotinib; Lapatinib; Carbozantinib; Lenalidomide; ABT-263 ( Navitoclax); ABT-199 (Venetoclax) and analogs or derivatives thereof as understood by those of skill in the art. In certain embodiments, the chemotherapeutic agent is an antibody that can be used alone or in combination with one or more of the aforementioned chemotherapeutic agents. In some embodiments, the antibody is selected from bevacizumab (Avastin®); Mapatumumab; Nivolumab (Opdivo®); Pembrolizumab (Keytruda®) and analogs or derivatives thereof as understood by those of skill in the art. In certain embodiments, the chemotherapeutic is a radioisotope that can be used alone or in combination with one or more of the aforementioned chemotherapeutic agents. In one embodiment, the radioisotope is ⁹⁰Y loaded on glass or resin microspheres.

5.5. Methods of treatment

[0060] In certain embodiments, the methods provided herein include treatment of liver cancer comprising administering a caspase inhibitor and a chemotherapeutic agent. In one embodiment, the methods are for treatment of liver cancer in combination with other therapies for the treatment of liver cancer. Without being bound to any particular theory, it is believed that the caspase inhibitors used in the methods provided herein act by inhibiting apoptosis and/or inflammation and the generation of subcellular fragments, known as microparticles, and signaling systems that may promote liver cancer for example as described in McDaniel, K. et al. Functional role of microparticles in gastrointestinal malignancies. Ann. Transl. Med. 2013; 4: 1-8.

[0061] In certain embodiments, the methods provided herein include treatment of liver cancer resulting from viral infections. In one embodiment, the viral infection is hepatitis C (HCV). In another embodiment the viral infection is hepatitis B (HBV).

[0062] In certain embodiments, the methods provided herein include treatment of liver cancer resulting from alcoholic liver disease. In one embodiment, the alcoholic liver disease is alcoholic hepatitis. In another embodiment the alcoholic liver disease is alcoholic liver cirrhosis.

[0063] In certain embodiments, the methods provided herein include treatment of liver cancer resulting from cryptogenic liver cirrhosis where the cause of liver cirrhosis is not known.

[0064] In certain embodiments, the methods provided herein include treatment of liver cancer resulting from chronic cholestatic liver disease. In one embodiment, the chronic cholestatic liver disease is primary biliary cirrhosis (PBC). In another embodiment the chronic cholestatic liver disease is primary sclerosing cholangitis (PSC).

[0065] In certain embodiments, the methods provided herein include treatment of liver cancer resulting parasitic infection. In one embodiment, the parasitic infection causes schistosomiasis. [0066] In certain embodiments, the methods provided herein include treatment of liver cancer resulting from ingestion of food-borne toxins. In one embodiment, the food-borne toxin is mycotoxin aflatoxin B 1.

[0067] In certain embodiments, the methods provided herein include treatment of liver cancer resulting from an inflammatory bowel disease. In one embodiment, the inflammatory bowel disease is ulcerative colitis.

[0068] In one embodiment, the methods provided herein include the treatment of liver cancer wherein the liver cancer is hepatocellular carcinoma.

[0069] In one embodiment, the methods provided herein include the treatment of liver cancer wherein the liver cancer is cholangiocarcinoma.

[0070] In certain embodiments, the exact cause of liver cancer is not known.

[0071] In certain embodiments, provided are methods for treatment of liver cancer for patients who have failed conventional therapy Exemplary conventional therapy for liver cancer is described by Schlachterman, A et al. Current and future treatments for hepatocellular carcinoma. World J. Gasteroenterol. 2015; 21 :8478-8491, Bruix, J. et al. Liver cancer:

Approaching a personalized care. J. Hepatology 2015; 62: S144-S156, incorporated by reference herein in their entirety.

[0072] In certain embodiments, the methods provided herein include treatment of liver cancer comprising administering a combination of a caspase inhibitor and a chemotherapeutic agent, wherein the combination is administered prior to surgical resection. In certain

embodiments, the methods provided herein include treatment of liver cancer comprising administering a combination of a caspase inhibitor and a chemotherapeutic agent, wherein the combination is administered after surgical resection. In certain embodiments, the methods provided herein include treatment of liver cancer comprising administering IDN-7314 and a chemotherapeutic agent prior to surgical resection. In certain embodiment, the methods provided herein include treatment of liver cancer comprising administering IDN-7314 and a

chemotherapeutic agent after surgical resection.

[0073] In certain embodiments, the methods provided herein include treatment of liver cancer comprising administering a combination of a caspase inhibitor and a TACE (also know n as HAI) involving hepatic artery infusion of chemotherapeutic agents such as Doxorubicin; Cisplatin; mitomycin C or floxuridine (FUDR) usually suspended in a lipid vehicle such as Lipiodol®.

[0074] In certain embodiments, the caspase inhibitors and therapeutic agents provided herein are administered in combination with a third agent or radiation therapy known to treat liver cancer.

[0075] In certain embodiments, dosages lower than those which have been or are currently being used to treat liver cancer combination therapies provided herein. For those agents that are approved for clinical use, recommended dosages are described in, for example, Hardman et al, eds., 1996, Goodman & Gilman's The Pharmacological Basis Of Basis Of Therapeutics 9^th Ed, Mc-Graw-Hill, New York; Physician's Desk Reference (PDR) 57^th Ed., 2003, Medical

Economics Co., Inc., Montvale, NJ, which are incorporated herein by reference in their entireties. The dosages given will depend on absorption, inactivation and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens and schedules should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions.

[0076] In certain embodiments, the methods provided herein include treatment of liver cancer comprising administering a caspase inhibitor, a chemotherapeutic agent and one or more additional agent selected from 5-fluorouracil (5-FU); doxorubicin (Adriamycin); cisplatin; sorafenib ( Nexavar®); Doxorubicin; Cisplatin; mitomycin C, floxuridine (FUDR), Sunitinib; ramucirumab (Cyramza®); regorafenib (Stivagra®); Lenvatinib; Brivanib; Tivantinib;

Linifanib; Foretinib; Refametinib; Selumetinib; Erlotinib; Lapatinib; Carbozantinib;

Lenalidomide; ABT-263 ( Navitoclax); ABT-199 (Venetoclax) and analogs or derivatives thereof as understood by those of skill in the art. In certain embodiments, the chemotherapeutic agent is an antibody that can be used alone or in combination with one or more of the aforementioned chemotherapeutic agents. In some embodiments, the antibody is selected from bevacizumab (Avastin®); Mapatumumab; Nivolumab (Opdivo®); Pembrolizumab (Keytruda®) and analogs or derivatives thereof as understood by those of skill in the art. In certain embodiments, the chemotherapeutic is a radioisotope that can be used alone or in combination with one or more of the aforementioned chemotherapeutic agents. In one embodiment, the radioisotope is Y loaded on glass or resin microspheres and analogs or derivatives thereof as understood by those of skill in the art.

[0077] In various embodiments, the combinations provided herein are administered less than 5 minutes apart, less than 30 minutes apart, 1 hour apart, at about 1 hour apart, at about 1 to about 2 hours apart, at about 2 hours to about 3 hours apart, at about 3 hours to about 4 hours apart, at about 4 hours to about 5 hours apart, at about 5 hours to about 6 hours apart, at about 6 hours to about 7 hours apart, at about 7 hours to about 8 hours apart, at about 8 hours to about 9 hours apart, at about 9 hours to about 10 hours apart, at about 10 hours to about 11 hours apart, at about 11 hours to about 12 hours apart, at about 12 hours to 18 hours apart, 18 hours to 24 hours apart, 24 hours to 36 hours apart, 36 hours to 48 hours apart, 48 hours to 52 hours apart, 52 hours to 60 hours apart, 60 hours to 72 hours apart, 72 hours to 84 hours apart, 84 hours to 96 hours apart, or 96 hours to 120 hours part. In certain embodiments, two or more therapies are administered within the same patient visit.

[0078] In certain embodiments, the caspase inhibitors and chemotherapeutic agents provided herein and optionally an additional therapy are administered to a patient, for example, a mammal, such as a human, in a sequence and within a time interval such that the compounds provided herein can act together with the additional therapy to provide an increased benefit than if they were administered otherwise. For example, a caspase inhibitor, a chemotherapeutic agent and a third chemotherapeutic agent can be administered at the same time or sequentially in any order at different points in time; however, if not administered at the same time, they should be administered sufficiently close in time so as to provide the desired therapeutic or prophylactic effect. In one embodiment, the compounds provided herein and optionally an additional therapy exert their effect at times which overlap. Each compound can be administered separately, in any appropriate form and by any suitable route. In other embodiments, the combination provided herein is administered before, concurrently or after administration of the third chemotherapeutic agent.

[0079] The caspase inhibitor compounds and chemotherapeutic agent provided herein and optionally one or more additional agents can act additively or synergistically. In one

embodiment, the caspase inhibitor compounds and the chemotherapeutic agent provided herein can act additively or synergistically with another chemotherapeutic agent. In one embodiment, the compounds provided herein are administered concurrently, optionally with another chemotherapeutic agent, with in the same pharmaceutical composition. In another embodiment, the compounds provided herein are administered concurrently, optionally with another chemotherapeutic agent, in separate pharmaceutical compositions. In still another embodiment, the compounds provided herein are administered with another chemotherapeutic agent, prior to or subsequent to administration of the third chemotherapeutic agent. Also contemplated are administration of the compounds provided herein by the same or different routes of

administration, e.g., oral, parenteral or via transarteial chemoembolization (TACE).

[0080] In certain embodiments, the additional chemotherapeutic agents administered in combination with caspase inhibitors according to the methods provided herein can include, but are not limited to, any compounds currently in preclinical or clinical development for treatment of liver cancer, for example, therapeutic vaccines such as TroVax ®, liver cell vaccines (alone or in combination with GM-CSF) or other chemotherapeutic agents

5.6. Preparation of the compounds

[0081] The compounds for use in the methods provided herein can be prepared by using routine synthetic procedures. Exemplary procedures for the preparation of caspase inhibitors used herein are described in US 6,197,750; 6,515,173; 6,525,024; 6,544,951; 6,790,989;

6,969,703; 7,053,056; 7,157,430; 7, 183,260; 7,692,038, and in Linton S. et al. J. Med Chem. 2005;48: 6779-6782, Ueno H. et al. Biorg. Med. Chem. Lett. 2009; 19: 199-102, each of which is incorporated by reference herein in its entirety.

5.7. Formulation of pharmaceutical compositions

[0082] The pharmaceutical compositions provided herein contain therapeutically effective amounts of one or more of compounds provided herein that are useful in the prevention, treatment, or amelioration of one or more of the symptoms of liver cancer and a

pharmaceutically acceptable carrier.

[0083] The compounds are formulated into suitable pharmaceutical preparations such as solutions, suspensions, tablets, dispersible tablets, pills, capsules, powders, sustained release formulations or elixirs, for oral administration or in sterile solutions or suspensions for parenteral administration, as well as transdermal patch preparation and dry powder inhalers. In one embodiment, the compounds described above are formulated into pharmaceutical compositions using techniques and procedures well known in the art {see, e.g., Remington's Pharmaceutical Sciences, 20^th eds., Mack Publishing, Easton PA (2000)). [0084] In the compositions, effective concentrations of one or more compounds or pharmaceutically acceptable derivatives is (are) mixed with a suitable pharmaceutical carrier or vehicle. The compounds may be derivatized as the corresponding salts, esters, acids, bases, solvates, hydrates or prodrugs prior to formulation, as described above. The concentrations of the compounds in the compositions are effective for delivery of an amount, upon administration, that treats, prevents, or ameliorates one or more of the symptoms of liver cancer.

[0085] In one embodiment, the compositions are formulated for single dosage

administration. To formulate a composition, the weight fraction of compound is dissolved, suspended, dispersed or otherwise mixed in a selected vehicle at an effective concentration such that the treated condition is relieved or ameliorated. Pharmaceutical carriers or vehicles suitable for administration of the compounds provided herein include any such carriers known to those skilled in the art to be suitable for the particular mode of administration.

[0086] In addition, the compounds may be formulated as the sole pharmaceutically active ingredient in the composition or may be combined with other active ingredients. Liposomal suspensions, including tissue-targeted liposomes, such as tumor-targeted liposomes, may also be suitable as pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art. For example, liposome formulations may be prepared as known in the art. Briefly, liposomes such as multilamellar vesicles (MLV's) may be formed by drying down egg phosphatidyl choline and brain phosphatidyl serine (7:3 molar ratio) on the inside of a flask. A solution of a compound provided herein in phosphate buffered saline (PBS) lacking divalent cations is added and the flask shaken until the lipid film is dispersed. The resulting vesicles are washed to remove unencapsulated compound, pelleted by centrifugation, and then resuspended in PBS.

[0087] The active compound is included in the pharmaceutically acceptable carrier in an amount sufficient to exert a therapeutically useful effect in the absence of undesirable side effects on the patient treated. The therapeutically effective concentration may be determined empirically by testing the compounds in in vitro and in vivo systems known in the art and then extrapolated therefrom for dosages for humans.

[0088] The concentration of active compound in the pharmaceutical composition will depend on absorption, inactivation and excretion rates of the active compound, the physicochemical characteristics of the compound, the dosage schedule, and amount administered as well as other factors known to those of skill in the art. For example, the amount that is delivered is sufficient to ameliorate one or more of the symptoms of liver cancer.

[0089] In one embodiment, a therapeutically effective dosage should produce a serum concentration of an active ingredient of from about 0.1 ng/ml to about 50-100 μg/ml, from about 0.5 ng/ml to about 80 μg/ml, from about 1 ng/ml to about 60 μg/ml, from about 5 ng/ml to about 50 μg/ml, from about 5 ng/ml to about 40 μg/ml, from about 10 ng/ml to about 35 μg/ml, from about 10 ng/ml to about 25 μg/ml, from about 10 ng/ml to about 10 μg/ml, from about 25 ng/ml to about 10 μg/ml, from about 50 ng/ml to about 10 μg/ml, from about 50 ng/ml to about 5 μg/ml, from about 100 ng/ml to about 5 μg/ml, from about 200 ng/ml to about 5 μg/ml, from about 250 ng/ml to about 5 μg/ml, from about 500 ng/ml to about 5 μg/ml, from about 1 μg/ml to about 50 μg/ml, from about 0.1 ng/ml to about 5 ng/ml, from about 1 ng/ml to about 10 ng/ml or from about 1 μg/ml to about 10 μg/ml. The pharmaceutical compositions, in certain

embodiments, should provide a dosage of from about 0.001 mg to about 2000 mg of compound per kilogram of body weight per day, from about 0.002 mg to about 1000 mg of compound per kilogram of body weight per day, from about 0.005 mg to about 500 mg of compound per kilogram of body weight per day /,, from about 0.005 mg to about 250 mg of compound per kilogram of body weight per day /,, from about 0.005 mg to about 200 mg of compound per kilogram of body weight per day /,, from about 0.005 mg to about 100 mg of compound per kilogram of body weight per day /,, from about 0.001 mg to about 0.005 mg of compound per kilogram of body weight per day /,, from about 0.01 mg to about 100 mg of compound per kilogram of body weight per day /,, from about 0.02 mg to about 100 mg of compound per kilogram of body weight per day /,, from about 0.05 mg to about 100 mg of compound per kilogram of body weight per day /,, from about 0.1 mg to about 100 mg of compound per kilogram of body weight per day /,, from about 0.5 mg to about 100 mg of compound per kilogram of body weight per day /,, from about 0.75 mg to about 100 mg of compound per kilogram of body weight per day /,, from about 1 mg to about 100 mg of compound per kilogram of body weight per day, from about 1 mg to about 10 mg of compound per kilogram of body weight per day, from about 0.001 mg to about 5 mg of compound per kilogram of body weight per day, from about 200 mg to about 2000 mg of compound per kilogram of body weight per day, or from about 10 mg to about 100 mg of compound per kilogram of body weight per day. Pharmaceutical dosage unit forms are prepared to provide from about 1 mg to about 1000 mg, from about 1 mg to about 800 mg, from about 5 mg to about 800 mg, from about 1 mg to about 100 mg, from about 1 mg to about 50 mg, from about 5 mg to about 100 mg, from about 10 mg to about 50 mg, from about 10 mg to about 100 mg, from about 25 mg to about 50 mg and from about 10 mg to about 500 mg of the essential active ingredient or a combination of essential ingredients per dosage unit form.

[0090] The active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at intervals of time. It is understood that the precise dosage and duration of treatment is a function of the disease being treated and may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test data. It is to be noted that concentrations and dosage values may also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed compositions.

[0091] Pharmaceutically acceptable derivatives include acids, bases and esters, salts, esters, hydrates, solvates and prodrug forms. The derivative is selected such that its pharmacokinetic properties are superior to the corresponding neutral compound.

[0092] Thus, effective concentrations or amounts of one or more of the compounds described herein or pharmaceutically acceptable derivatives thereof are mixed with a suitable

pharmaceutical carrier or vehicle for systemic, topical or local administration to form

pharmaceutical compositions. Compounds are included in an amount effective for ameliorating one or more symptoms of, or for treating or preventing recurrence of liver cancer. The concentration of active compound in the composition will depend on absorption, inactivation, excretion rates of the active compound, the dosage schedule, amount administered, particular formulation as well as other factors known to those of skill in the art.

[0093] The compositions are intended to be administered by a suitable route, including orally, parenterally, rectally, topically, locally and via nasogastric or orogastric tube. For oral administration, capsules and tablets can be used. The compositions are in liquid, semi-liquid or solid form and are formulated in a manner suitable for each route of administration. In one embodiment, modes of administration include parenteral and oral modes of administration. In certain embodiments, oral administration is contemplated.

[0094] Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include any of the following components: a sterile diluent, such as water for injection, saline solution, fixed oil, polyethylene glycol, glycerine, propylene glycol, dimethyl acetamide or other synthetic solvent; antimicrobial agents, such as benzyl alcohol and methyl parabens; antioxidants, such as ascorbic acid and sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid (EDTA); buffers, such as acetates, citrates and phosphates; and agents for the adjustment of tonicity such as sodium chloride or dextrose. Parenteral

preparations can be enclosed in ampules, disposable syringes or single or multiple dose vials made of glass, plastic or other suitable material.

[0095] In instances in which the compounds exhibit insufficient solubility, methods for solubilizing compounds may be used. Such methods are known to those of skill in this art, and include, but are not limited to, using co-solvents, such as dimethyl sulfoxide (DMSO), using surfactants, such as TWEEN®, or dissolution in aqueous sodium bicarbonate.

[0096] Upon mixing or addition of the compound(s), the resulting mixture may be a solution, suspension, emulsion or the like. The form of the resulting mixture depends upon a number of factors, including the intended mode of administration and the solubility of the compound in the selected carrier or vehicle. The effective concentration is sufficient for ameliorating the symptoms of the disease, disorder or condition treated and may be empirically determined.

[0097] The pharmaceutical compositions are provided for administration to humans and animals in unit dosage forms, such as tablets, capsules, pills, powders, granules, sterile parenteral solutions or suspensions, and oral solutions or suspensions, and oil / water emulsions containing suitable quantities of the compounds or pharmaceutically acceptable derivatives thereof. The pharmaceutically therapeutically active compounds and derivatives thereof are formulated and administered in unit dosage forms or multiple dosage forms. Unit dose forms as used herein refer to physically discrete units suitable for human and animal subjects and packaged individually as is known in the art. Each unit dose contains a predetermined quantity of the therapeutically active compound sufficient to produce the desired therapeutic effect, in association with the required pharmaceutical carrier, vehicle or diluent. Examples of unit dose forms include ampules and syringes and individually packaged tablets or capsules. Unit dose forms may be administered in fractions or multiples thereof. A multiple dose form is a plurality of identical unit dosage forms packaged in a single container to be administered in segregated unit dose form. Examples of multipledose forms include vials, bottles of tablets or capsules or bottles of pints or gallons. Hence, multiple dose form is a multiple of unit doses which are not segregated in packaging.

[0098] Sustained-release preparations can also be prepared. Suitable examples of sustained- release preparations include semipermeable matrices of solid hydrophobic polymers containing the compound provided herein, which matrices are in the form of shaped articles, e.g., films, or microcapsule. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides, copolymers of L-glutamic acid and ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-gly colic acid copolymers such as the LUPRON DEPOT™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3- hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated compound remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37 °C, resulting in a loss of biological activity and possible changes in their structure. Rational strategies can be devised for stabilization depending on the mechanism of action involved. For example, if the aggregation mechanism is discovered to be intermolecular S--S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions

[0099] Dosage forms or compositions containing active ingredient in the range of 0.001%to 100% active ingredient, 0.002% to 100% active ingredient, 0.005% to 90% active ingredient, 0.01% to 100% active ingredient, 0.05% to 100% active ingredient, 0.05% to 90% active ingredient, 0.1% to 100% active ingredient, 0.1% to 1% active ingredient, 0.1% to 0.5% active ingredient, 1% to 100%) active ingredient, 1% to 99% active ingredient, 1% to 98% active ingredient, 1% to 97% active ingredient, 1% to 96% active ingredient, 1% to 95% active ingredient, 5% to 95% active ingredient, 10% to 100%) active ingredient, 10% to 95% active ingredient, 15% to 95% active ingredient, 20% to 95% active ingredient, 25% to 100%) active ingredient, 50% to 100% active ingredient, 50% to 95% active ingredient, 60% to 95% active ingredient or 75% to 100% active ingredient, with the balance made up from nontoxic carrier may be prepared. For oral administration, a pharmaceutically acceptable nontoxic composition is formed by the incorporation of any of the normally employed excipients, such as, for example pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, talcum, cellulose derivatives, sodium crosscarmellose, glucose, sucrose, magnesium carbonate or sodium saccharin. Such compositions include solutions, suspensions, tablets, capsules, powders and sustained release formulations, such as, but not limited to, implants and microencapsulated delivery systems, and biodegradable, biocompatible polymers, such as collagen, ethylene vinyl acetate, polyanhydrides, polyglycolic acid, polyorthoesters, polylactic acid and others. Methods for preparation of these compositions are known to those skilled in the art. The contemplated compositions may contain 0.001% to 100% active ingredient, in one embodiment or 75-95% active ingredient.

[00100] The active compounds or pharmaceutically acceptable derivatives may be prepared with carriers that protect the compound against rapid elimination from the body, such as time release formulations or coatings.

[00101] The compositions may include other active compounds to obtain desired

combinations of properties. The compounds provided herein, or pharmaceutically acceptable derivatives thereof as described herein, may also be advantageously administered for therapeutic or prophylactic purposes together with another pharmacological agent known in the general art to be of value in treating liver cancer. It is to be understood that such combination therapy constitutes a further aspect of the compositions and methods of treatment provided herein.

Compositions for oral administration

[00102] Oral pharmaceutical dosage forms are either solid, gel or liquid. The solid dosage forms are tablets, capsules, granules, and bulk powders. Types of oral tablets include compressed, chewable lozenges and tablets which may be enteric coated, sugarcoated or film coated. Capsules may be hard or soft gelatin capsules, while granules and powders may be provided in non-effervescent or effervescent form with the combination of other ingredients known to those skilled in the art.

[00103] In certain embodiments, the formulations are solid dosage forms, such as capsules or tablets. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder; a diluent; a disintegrating agent; a lubricant; a glidant; a sweetening agent; and a flavoring agent.

[00104] Examples of binders include microcrystalline cellulose, gum tragacanth, glucose solution, acacia mucilage, gelatin solution, sucrose and starch paste. Lubricants include talc, starch, magnesium or calcium stearate, lycopodium and stearic acid. Diluents include, for example, lactose, sucrose, starch, kaolin, salt, mannitol and dicalcium phosphate. Glidants include, but are not limited to, colloidal silicon dioxide. Disintegrating agents include crosscarmellose sodium, sodium starch glycolate, alginic acid, corn starch, potato starch, bentonite, methylcellulose, agar and carboxymethylcellulose. Coloring agents include, for example, any of the approved certified water soluble FD and C dyes, mixtures thereof; and water insoluble FD and C dyes suspended on alumina hydrate. Sweetening agents include sucrose, lactose, mannitol and artificial sweetening agents such as saccharin, and any number of spray dried flavors. Flavoring agents include natural flavors extracted from plants such as fruits and synthetic blends of compounds which produce a pleasant sensation, such as, but not limited to peppermint and methyl salicylate. Wetting agents include propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate and polyoxyethylene laural ether.

Emeticcoatings include fatty acids, fats, waxes, shellac, ammoniated shellac and cellulose acetate phthalates. Film coatings include hydroxyethylcellulose, sodium carboxymethylcellulose, polyethylene glycol 4000 and cellulose acetate phthalate.

[00105] If oral administration is desired, the compound could be provided in a composition that protects it from the acidic environment of the stomach. For example, the composition can be formulated in an enteric coating that maintains its integrity in the stomach and releases the active compound in the intestine. The composition may also be formulated in combination with an antacid or other such ingredient.

[00106] When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil. In addition, dosage unit forms can contain various other materials which modify the physical form of the dosage unit, for example, coatings of sugar and other enteric agents. The compounds can also be administered as a component of an elixir, suspension, syrup, wafer, sprinkle, chewing gum or the like. A syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors. [00107] The active materials can also be mixed with other active materials which do not impair the desired action, or with materials that supplement the desired action, such as antacids, H2 blockers, and diuretics. The active ingredient is a compound or pharmaceutically acceptable derivative thereof as described herein. Higher concentrations, up to about 98% by weight of the active ingredient may be included.

[00108] Pharmaceutically acceptable carriers included in tablets are binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, and wetting agents. Enteric coated tablets, because of the enteric coating, resist the action of stomach acid and dissolve or disintegrate in the neutral or alkaline intestines. Sugarcoated tablets are compressed tablets to which different layers of pharmaceutically acceptable substances are applied. Film coated tablets are compressed tablets which have been coated with a polymer or other suitable coating. Multiple compressed tablets are compressed tablets made by more than one compression cycle utilizing the pharmaceutically acceptable substances previously mentioned. Coloring agents may also be used in the above dosage forms. Flavoring and sweetening agents are used in

compressed tablets, sugarcoated, multiple compressed and chewable tablets. Flavoring and sweetening agents are especially useful in the formation of chewable tablets and lozenges.

[00109] Liquid oral dosage forms include aqueous solutions, emulsions, suspensions, solutions and/or suspensions reconstituted from non-effervescent granules and effervescent preparations reconstituted from effervescent granules. Aqueous solutions include, for example, elixirs and syrups. Emulsions are either oil in-water or water in oil.

[00110] Elixirs are clear, sweetened, hydroalcoholic preparations. Pharmaceutically acceptable carriers used in elixirs include solvents. Syrups are concentrated aqueous solutions of a sugar, for example, sucrose, and may contain a preservative. An emulsion is a two phase system in which one liquid is dispersed in the form of small globules throughout another liquid. Pharmaceutically acceptable carriers used in emulsions are non-aqueous liquids, emulsifying agents and preservatives. Suspensions use pharmaceutically acceptable suspending agents and preservatives. Pharmaceutically acceptable substances used in non-effervescent granules, to be reconstituted into a liquid oral dosage form, include diluents, sweeteners and wetting agents. Pharmaceutically acceptable substances used in effervescent granules, to be reconstituted into a liquid oral dosage form, include organic acids and a source of carbon dioxide. Coloring and flavoring agents are used in all of the above dosage forms. [00111] Solvents include glycerin, sorbitol, ethyl alcohol and syrup. Examples of preservatives include glycerin, methyl and propylparaben, benzoic add, sodium benzoate and alcohol. Examples of non-aqueous liquids utilized in emulsions include mineral oil and cottonseed oil. Examples of emulsifying agents include gelatin, acacia, tragacanth, bentonite, and surfactants such as polyoxyethylene sorbitan monooleate. Suspending agents include sodium carboxymethylcellulose, pectin, tragacanth, Veegum and acacia. Diluents include lactose and sucrose. Sweetening agents include sucrose, syrups, glycerin and artificial sweetening agents such as saccharin. Wetting agents include propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate and polyoxyethylene lauryl ether. Organic acids include citric and tartaric acid. Sources of carbon dioxide include sodium bicarbonate and sodium carbonate. Coloring agents include any of the approved certified water soluble FD and C dyes, and mixtures thereof. Flavoring agents include natural flavors extracted from plants such fruits, and synthetic blends of compounds which produce a pleasant taste sensation.

[00112] For a solid dosage form, the solution or suspension, in for example propylene carbonate, vegetable oils or triglycerides, can be encapsulated in a gelatin capsule. Such solutions, and the preparation and encapsulation thereof, are disclosed in U.S. Patent Nos 4,328,245; 4,409,239; and 4,410,545. For a liquid dosage form, the solution, e.g., for example, in a polyethylene glycol, may be diluted with a sufficient quantity of a pharmaceutically acceptable liquid carrier, e.g., water, to be easily measured for administration.

[00113] Alternatively, liquid or semisolid oral formulations may be prepared by dissolving or dispersing the active compound or salt in vegetable oils, glycols, triglycerides, propylene glycol esters (e.g., propylene carbonate) and other such carriers, and encapsulating these solutions or suspensions in hard or soft gelatin capsule shells. Other useful formulations include, but are not limited to, those containing a compound provided herein, a dialkylated mono- or poly-alkylene glycol, including, but not limited to, 1,2-dimethoxymethane, diglyme, triglyme, tetraglyme, polyethylene glycol-350-dimethyl ether, polyethylene glycol-550-dimethyl ether, polyethylene glycol-750-dimethyl ether wherein 350, 550 and 750 refer to the approximate average molecular weight of the polyethylene glycol, and one or more antioxidants, such as butylated

hydroxytoluene (BHT), butylated hydroxyanisole (BHA), propyl gallate, vitamin E,

hydroquinone, hydroxycoumarins, ethanolamine, lecithin, cephalin, ascorbic acid, malic acid, sorbitol, phosphoric acid, thiodipropionic acid and its esters, and dithiocarbamates. [00114] Other formulations include, but are not limited to, aqueous alcoholic solutions including a pharmaceutically acceptable acetal. Alcohols used in these formulations are any pharmaceutically acceptable water-miscible solvents having one or more hydroxyl groups, including, but not limited to, propylene glycol and ethanol. Acetals include, but are not limited to, di(lower alkyl) acetals of lower alkyl aldehydes such as acetaldehyde diethyl acetal.

[00115] In all embodiments, tablets and capsules formulations may be coated as known by those of skill in the art in order to modify or sustain dissolution of the active ingredient. Thus, for example, they may be coated with a conventional enterically digestible coating, such as phenylsalicylate, waxes and cellulose acetate phthalate.

Injectables, solutions and emulsions

[00116] Parenteral administration, generally characterized by injection, either subcutaneously, intramuscularly or intravenously is also contemplated herein. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Suitable excipients are, for example, water, saline, dextrose, glycerol or ethanol. In addition, if desired, the pharmaceutical compositions to be administered may also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, stabilizers, solubility enhancers, and other such agents, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate and cyclodextrins. Implantation of a slow release or sustained release system, such that a constant level of dosage is maintained is also contemplated herein. Briefly, a compound provided herein is dispersed in a solid inner matrix, e.g., polymethylmethacrylate, polybutylmethacrylate, plasticized or unplasticized polyvinylchloride, plasticized nylon, plasticized polyethyleneterephthalate, natural rubber, polyisoprene, polyisobutylene,

polybutadiene, polyethylene, ethylene-vinylacetate copolymers, silicone rubbers,

polydimethylsiloxanes, silicone carbonate copolymers, hydrophilic polymers such as hydrogels of esters of acrylic and methacrylic acid, collagen, cross-linked polyvinylalcohol and cross- linked partially hydrolyzed polyvinyl acetate, that is surrounded by an outer polymeric membrane, e.g., polyethylene, polypropylene, ethylene/propylene copolymers, ethylene/ethyl acrylate copolymers, ethylene/vinylacetate copolymers, silicone rubbers, polydimethyl siloxanes, neoprene rubber, chlorinated polyethylene, polyvinylchloride, vinylchloride copolymers with vinyl acetate, vinylidene chloride, ethylene and propylene, ionomer polyethylene terephthalate, butyl rubber epichlorohydrin rubbers, ethylene/vinyl alcohol copolymer, ethylene/vinyl acetate/vinyl alcohol terpolymer, and ethylene/vinyloxyethanol copolymer, that is insoluble in body fluids. The compound diffuses through the outer polymeric membrane in a release rate controlling step. The percentage of active compound contained in such parenteral compositions is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the subject.

[00117] Parenteral administration of the compositions includes intravenous, subcutaneous and intramuscular administrations. Preparations for parenteral administration include sterile solutions ready for injection, sterile dry soluble products, such as lyophilized powders, ready to be combined with a solvent just prior to use, including hypodermic tablets, sterile suspensions ready for injection, sterile dry insoluble products ready to be combined with a vehicle just prior to use and sterile emulsions. The solutions may be either aqueous or nonaqueous.

[00118] If administered intravenously, suitable carriers include physiological saline or phosphate buffered saline (PBS), and solutions containing thickening and solubilizing agents, such as glucose, polyethylene glycol, and polypropylene glycol and mixtures thereof.

[00119] Pharmaceutically acceptable carriers used in parenteral preparations include aqueous vehicles, nonaqueous vehicles, antimicrobial agents, isotonic agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, emulsifying agents, sequestering or chelating agents and other pharmaceutically acceptable substances.

[00120] Examples of aqueous vehicles include Sodium Chloride Injection, Ringers Injection, Isotonic Dextrose Injection, Sterile Water Injection, Dextrose and Lactated Ringers Injection. Nonaqueous parenteral vehicles include fixed oils of vegetable origin, cottonseed oil, corn oil, sesame oil and peanut oil. Antimicrobial agents in bacteriostatic or fungistatic concentrations must be added to parenteral preparations packaged in multiple dose containers which include phenols or cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl

phydroxybenzoic acid esters, thimerosal, benzalkonium chloride and benzethonium chloride. Isotonic agents include sodium chloride and dextrose. Buffers include phosphate and citrate. Antioxidants include sodium bisulfate. Local anesthetics include procaine hydrochloride.

Suspending and dispersing agents include sodium carboxymethylcelluose, hydroxypropyl methylcellulose and polyvinylpyrrolidone. Emulsifying agents include Polysorbate 80

(TWEEN® 80). A sequestering or chelating agent of metal ions includes EDTA. Pharmaceutical carriers also include ethyl alcohol, polyethylene glycol and propylene glycol for water miscible vehicles and sodium hydroxide, hydrochloric acid, citric acid or lactic acid for pH adjustment.

[00121] The concentration of the pharmaceutically active compound is adjusted so that an injection provides an effective amount to produce the desired pharmacological effect. The exact dose depends on the age, weight and condition of the patient or animal as is known in the art.

[00122] The unit dose parenteral preparations are packaged in an ampule, a vial or a syringe with a needle. All preparations for parenteral administration must be sterile, as is known and practiced in the art.

[00123] Illustratively, intravenous or intra-arterial infusion of a sterile aqueous solution containing an active compound is an effective mode of administration. Another embodiment is a sterile aqueous or oily solution or suspension containing an active material injected as necessary to produce the desired pharmacological effect.

[00124] Injectables are designed for local and systemic administration. In certain

embodiments, a therapeutically effective dosage is formulated to contain a concentration of at least about 0.1% w/w up to about 90% w/w or more, or more than 1% w/w of the active compound to the treated tissue(s). The active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at intervals of time. It is understood that the precise dosage and duration of treatment is a function of the tissue being treated and may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test data. It is to be noted that concentrations and dosage values may also vary with the age of the individual treated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the formulations, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed formulations.

[00125] The compound may be suspended in micronized or other suitable form or may be derivatized to produce a more soluble active product or to produce a prodrug. The form of the resulting mixture depends upon a number of factors, including the intended mode of

administration and the solubility of the compound in the selected carrier or vehicle. The effective concentration is sufficient for ameliorating the symptoms of the condition and may be empirically determined.

Lyophilized powders

[00126] Of interest herein are also lyophilized powders, which can be reconstituted for administration as solutions, emulsions and other mixtures. They may also be reconstituted and formulated as solids or gels.

[00127] The sterile, lyophilized powder is prepared by dissolving a compound provided herein, or a pharmaceutically acceptable derivative thereof, in a suitable solvent. The solvent may contain an excipient which improves the stability or other pharmacological component of the powder or reconstituted solution, prepared from the powder. Excipients that may be used include, but are not limited to, dextrose, sorbital, fructose, corn syrup, xylitol, glycerin, glucose, sucrose or other suitable agent. The solvent may also contain a buffer, such as citrate, sodium or potassium phosphate or other such buffer known to those of skill in the art at about neutral pH. Subsequent sterile filtration of the solution followed by lyophilization under standard conditions known to those of skill in the art provides the desired formulation. Generally, the resulting solution will be apportioned into vials for lyophilization. Each vial will contain a single dosage (10-1000 mg or 100-500 mg) or multiple dosages of the compound. The lyophilized powder can be stored under appropriate conditions, such as at about 4 degrees Celsius to room temperature.

[00128] Reconstitution of this lyophilized powder with water for injection provides a formulation for use in parenteral administration. For reconstitution, about 1-50 mg, 5-35 mg or about 9-30 mg of lyophilized powder, is added per mL of sterile water or other suitable carrier. The precise amount depends upon the selected compound. Such amount can be empirically determined.

Topical administration

[00129] Topical mixtures are prepared as described for the local and systemic administration. The resulting mixture may be a solution, suspension, emulsions or the like and are formulated as creams, gels, ointments, emulsions, solutions, elixirs, lotions, suspensions, tinctures, pastes, foams, aerosols, irrigations, sprays, suppositories, bandages, dermal patches or any other formulations suitable for topical administration.

[00130] The compounds or pharmaceutically acceptable derivatives thereof may be formulated as aerosols for topical application, such as by inhalation (see, e.g., U.S. Patent Nos. 4,044,126, 4,414,209, and 4,364,923, which describe aerosols for delivery of a steroid useful for treatment of inflammatory diseases, particularly asthma). These formulations for administration to the respiratory tract can be in the form of an aerosol or solution for a nebulizer, or as a microfine powder for insufflation, alone or in combination with an inert carrier such as lactose. In such a case, the particles of the formulation will have diameters of less than 50 microns or less than 10 microns.

[00131] The compounds may be formulated for local or topical application, such as for topical application to the skin and mucous membranes, such as in the eye, in the form of gels, creams, and lotions and for application to the eye or for intraci sternal or intraspinal application. Topical administration is contemplated for transdermal delivery and also for administration to the eyes or mucosa, or for inhalation therapies. Nasal solutions of the active compound alone or in combination with other pharmaceutically acceptable excipients can also be administered.

[00132] These solutions, particularly those intended for ophthalmic use, may be formulated as 0.01% - 10% isotonic solutions, pH about 5-7, with appropriate salts.

Compositions for other routes of administration

[00133] Other routes of administration, such as topical application, transdermal patches, and rectal administration are also contemplated herein.

[00134] For example, pharmaceutical dosage forms for rectal administration are rectal suppositories, capsules and tablets for systemic effect. Rectal suppositories are used herein mean solid bodies for insertion into the rectum which melt or soften at body temperature releasing one or more pharmacologically or therapeutically active ingredients. Pharmaceutically acceptable substances utilized in rectal suppositories are bases or vehicles and agents to raise the melting point. Examples of bases include cocoa butter (theobroma oil), glycerin gelatin, carbowax (polyoxyethylene glycol) and appropriate mixtures of mono, di and triglycerides of fatty acids. Combinations of the various bases may be used. Agents to raise the melting point of

suppositories include spermaceti and wax. Rectal suppositories may be prepared either by the compressed method or by molding. In certain embodiments, the weight of a rectal suppository is about 2 to 3 gm.

[00135] Tablets and capsules for rectal administration are manufactured using the same pharmaceutically acceptable substance and by the same methods as for formulations for oral administration. Sustained Release Compositions

[00136] Active ingredients such as the compounds provided herein can be administered by controlled release means or by delivery devices that are well known to those of ordinary skill in the art. Examples include, but are not limited to, those described in U.S. Patent Nos. : 3,845,770; 3,916,899; 3,536,809; 3,598, 123; 4,008,719; 5,674,533; 5,059,595; 5,591,767; 5, 120,548;

5,073,543; 5,639,476; 5,354,556; 5,639,480; 5,733,566; 5,739, 108; 5,891,474; 5,922,356;

5,972,891 ; 5,980,945; 5,993,855; 6,045,830; 6,087,324; 6, 1 13,943; 6, 197,350; 6,248,363;

6,264,970; 6,267,981 ; 6,376,461 ; 6,419,961 ; 6,589,548; 6,613,358 and 6,699,500 each of which is incorporated herein by reference. Such dosage forms can be used to provide slow or controlled release of one or more active ingredients using, for example, hydropropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or a combination thereof to provide the desired release profile in varying proportions. Suitable controlled release formulations known to those of ordinary skill in the art, including those described herein, can be readily selected for use with the active ingredients provided herein. Thus, the compositions provided encompass single unit dosage forms suitable for oral administration such as, but not limited to, tablets, capsules, gel caps, and caplets that are adapted for controlled release.

[00137] All controlled release pharmaceutical products have a common goal of improving drug therapy over that achieved by their non-controlled counterparts. Ideally, the use of an optimally designed controlled release preparation in medical treatment is characterized by a minimum of drug substance being employed to cure or control the condition in a minimum amount of time. Advantages of controlled release formulations include extended activity of the drug, reduced dosage frequency, and increased subject compliance. In addition, controlled release formulations can be used to affect the time of onset of action or other characteristics, such as blood levels of the drug, and can thus affect the occurrence of side (e.g., adverse) effects.

[00138] Most controlled release formulations are designed to initially release an amount of drug (active ingredient) that promptly produces the desired therapeutic effect, and gradually and continually release of other amounts of drug to maintain this level of therapeutic or prophylactic effect over an extended period of time. In order to maintain this constant level of drug in the body, the drug must be released from the dosage form at a rate that will replace the amount of drug being metabolized and excreted from the body. Controlled release of an active ingredient can be stimulated by various conditions including, but not limited to, pH, temperature, enzymes, water, or other physiological conditions or compounds.

[00139] In certain embodiments, the drug may be administered using intravenous infusion, an implantable osmotic pump, a transdermal patch, liposomes, or other modes of administration. In one embodiment, a pump may be used {see, Sefton, CRC Crit. Ref. Biomed. Eng. 1987; 14:201, Buchwald et al., Surgery 1980; 88:507, Saudek et al, N. Engl. J. Med. 1989; 321 : 574. In another embodiment, polymeric materials can be used. In yet another embodiment, a controlled release system can be placed in a subject at an appropriate site determined by a practitioner of skill, i.e., thus requiring only a fraction of the systemic dose {see, e.g., Goodson, Medical Applications of Controlled Release, vol. 2, 1984, pp. 115-138. Other controlled release systems are discussed in the review by Langer {Science 1990; 249: 1527-1533. The active ingredient can be dispersed in a solid inner matrix, e.g., polymethylmethacrylate, polybutylmethacrylate, plasticized or unplasticized polyvinylchloride, plasticized nylon, plasticized

polyethyleneterephthalate, natural rubber, polyisoprene, polyisobutylene, polybutadiene, polyethylene, ethylene-vinylacetate copolymers, silicone rubbers, polydimethylsiloxanes, silicone carbonate copolymers, hydrophilic polymers such as hydrogels of esters of acrylic and methacrylic acid, collagen, cross-linked polyvinylalcohol and cross-linked partially hydrolyzed polyvinyl acetate, that is surrounded by an outer polymeric membrane, e.g., polyethylene, polypropylene, ethylene/propylene copolymers, ethyl ene/ethyl acrylate copolymers,

ethylene/vinylacetate copolymers, silicone rubbers, polydimethyl siloxanes, neoprene rubber, chlorinated polyethylene, polyvinylchloride, vinylchloride copolymers with vinyl acetate, vinylidene chloride, ethylene and propylene, ionomer polyethylene terephthalate, butyl rubber epichlorohydrin rubbers, ethylene/vinyl alcohol copolymer, ethylene/vinyl acetate/vinyl alcohol terpolymer, and ethylene/vinyloxyethanol copolymer, that is insoluble in body fluids. The active ingredient then diffuses through the outer polymeric membrane in a release rate controlling step. The percentage of active ingredient in such parenteral compositions is highly dependent on the specific nature thereof, as well as the needs of the subject.

Targeted Formulations

[00140] The compounds provided herein, or pharmaceutically acceptable derivatives thereof, may also be formulated to be targeted to a particular tissue, receptor, or other area of the body of the subject to be treated. Many such targeting methods are well known to those of skill in the art. All such targeting methods are contemplated herein for use in the instant compositions. For non-limiting examples of targeting methods, see, e.g., U.S. Patent Nos. 6,316,652, 6,274,552, 6,271,359, 6,253,872, 6, 139,865, 6, 131,570, 6, 120,751, 6,071,495, 6,060,082, 6,048,736, 6,039,975, 6,004,534, 5,985,307, 5,972,366, 5,900,252, 5,840,674, 5,759,542 and 5,709,874.

[00141] In one embodiment, liposomal suspensions, including tissue-targeted liposomes, such as tumor-targeted liposomes, may also be suitable as pharmaceutically acceptable carriers.

These may be prepared according to methods known to those skilled in the art. For example, liposome formulations may be prepared as described in U.S. Patent No. 4,522,811. Briefly, liposomes such as multilamellar vesicles (MLV's) may be formed by drying down egg phosphatidyl choline and brain phosphatidyl serine (7:3 molar ratio) on the inside of a flask. A solution of a compound provided herein in phosphate buffered saline lacking divalent cations (PBS) is added and the flask shaken until the lipid film is dispersed. The resulting vesicles are washed to remove unencapsulated compound, pelleted by centrifugation, and then resuspended in PBS.

Dosage and Unit Dosage Forms

[00142] In human therapeutics, the doctor will determine the posology which he considers most appropriate according to a preventive or curative treatment and according to the age, weight, stage of the disease and other factors specific to the subject to be treated. Generally, doses are from about 1 to about 1000 mg per day for an adult, or from about 5 to about 250 mg per day or from about 10 to 50 mg per day for an adult. In certain embodiments, doses are from about 5 to about 400 mg per day or 25 to 200 mg per day per adult. Dose rates of from about 50 to about 500 mg per day are also contemplated.

[00143] In certain embodiments, the amount of the compound or composition which will be effective in the treatment of colon cancer or prevention one or more symptoms thereof will vary with the nature and severity of the disease or condition, and the route by which the active ingredient is administered. The frequency and dosage will also vary according to factors specific for each subject depending on the specific therapy (e.g., therapeutic or prophylactic agents) administered, the severity of the disorder, disease, or condition, the route of administration, as well as age, body, weight, response, and the past medical history of the subject. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems. [00144] Exemplary doses of a composition include milligram or microgram amounts of the therapeutic agent and caspase inhibitor per kilogram of subject or sample weight (e.g., about 10 micrograms per kilogram to about 50 milligrams per kilogram, about 100 micrograms per kilogram to about 25 milligrams per kilogram, or about 100 microgram per kilogram to about 10 milligrams per kilogram). In certain embodiments, the dosage administered to a subject is between 0.20 mg/kg and 2.00 mg/kg, or between 0.30 mg/kg and 1.50 mg/kg of the subject's body weight.

[00145] In certain embodiments, the recommended daily dose range of the therapeutic agent and caspase inhibitor described herein for the conditions described herein lies within the range of from about 0.1 mg to about 1000 mg of each of the chemotherapeutic agent and caspase inhibitor per day, given as a single once-a-day dose or as divided doses throughout a day. In one embodiment, the daily dose is administered twice daily in equally divided doses. Specifically, a daily dose range should be from about 10 mg to about 200 mg per day, more specifically, between about 10 mg and about 150 mg per day, or even more specifically between about 25 and about 100 mg per day. It may be necessary to use dosages of the active ingredient outside the ranges disclosed herein in some cases, as will be apparent to those of ordinary skill in the art. Furthermore, it is noted that the clinician or treating physician will know how and when to interrupt, adjust, or terminate therapy in conjunction with subject response.

[00146] Different therapeutically effective amounts may be applicable for different diseases and conditions, as will be readily known by those of ordinary skill in the art. Similarly, amounts sufficient to prevent, manage, treat or ameliorate such disorders, but insufficient to cause, or sufficient to reduce, adverse effects associated with the compound described herein are also encompassed by the above described dosage amounts and dose frequency schedules. Further, when a subject is administered multiple dosages of a compound described herein, not all of the dosages need be the same. For example, the dosage administered to the subject may be increased to improve the prophylactic or therapeutic effect of the compound or it may be decreased to reduce one or more side effects that a particular subject is experiencing.

[00147] In one embodiment, the dosage of compounds described herein administered to prevent, treat, manage, or ameliorate a disorder, or one or more symptoms thereof in a subject is 0.1 mg/kg, 1 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg, 5 mg/kg, 6 mg/kg, 10 mg/kg, or 15 mg/kg or more of a subject's body weight. In another embodiment, the dosage of the compounds provided herein administered to prevent, treat, manage, or ameliorate a disorder, or one or more symptoms thereof in a subject is a unit dose of 0.1 mg to 200 mg, 0.1 mg to 100 mg, 0.1 mg to 50 mg, 0.1 mg to 25 mg, 0.1 mg to 20 mg, 0.1 mg to 15 mg, 0.1 mg to 10 mg, 0.1 mg to 7.5 mg, 0.1 mg to 5 mg, 0.1 to 2.5 mg, 0.25 mg to 20 mg, 0.25 to 15 mg, 0.25 to 12 mg, 0.25 to 10 mg, 0.25 mg to 7.5 mg, 0.25 mg to 5 mg, 0.5 mg to 2.5 mg, 1 mg to 20 mg, 1 mg to 15 mg, 1 mg to 12 mg, 1 mg to 10 mg, 1 mg to 7.5 mg, 1 mg to 5 mg, or 1 mg to 2.5 mg.

[00148] In certain embodiments, treatment or prevention can be initiated with one or more loading doses of the caspase inhibitor and chemotherapeutic agent are provided herein followed by one or more maintenance doses. In such embodiments, the loading dose can be, for instance, about 60 to about 400 mg per day, or about 100 to about 200 mg per day for one day to five weeks. The loading dose can be followed by one or more maintenance doses. Each maintenance does can be, independently, about from about 10 mg to about 200 mg per day, more specifically, between about 25 mg and about 150 mg per day, or even more specifically between about 25 mg and about 80 mg per day or between about 25 mg and about 50 mg per day. Maintenance doses can be administered daily and can be administered as single doses, or as divided doses.

[00149] In certain embodiments, a dose of the caspase inhibitor and chemotherapeutic agent provided herein can be administered to achieve a steady-state concentration of the active ingredient in blood or serum of the subject. The steady-state concentration can be determined by measurement according to techniques available to those of skill or can be based on the physical characteristics of the subject such as height, weight and age. In certain embodiments, a sufficient amount of a compound provided herein is administered to achieve a steady-state concentration in blood or serum of the subject of from about 300 to about 4000 ng/mL, from about 400 to about 1600 ng/mL, or from about 600 to about 1200 ng/mL. Loading doses can be administered to achieve steady-state blood or serum concentrations of about 1200 to about 8000 ng/mL, or about 2000 to about 4000 ng/mL for one to five days. Maintenance doses can be administered to achieve a steady-state concentration in blood or serum of the subject of from about 300 to about 4000 ng/mL, from about 400 to about 1600 ng/mL, or from about 600 to about 1200 ng/mL.

[00150] In certain embodiments, administration of the same compound may be repeated and the administrations may be separated by at least 1 day, 2 days, 3 days, 5 days, 10 days, 15 days, 30 days, 45 days, 2 months, 75 days, 3 months, or 6 months. In other embodiments,

administration of the same prophylactic or therapeutic agent may be repeated and the administration may be separated by at least at least 1 day, 2 days, 3 days, 5 days, 10 days, 15 days, 30 days, 45 days, 2 months, 75 days, 3 months, or 6 months.

[00151] In certain aspects, provided herein are unit dosages comprising a compound, or a pharmaceutically acceptable derivative thereof, in a form suitable for administration. Such forms are described in detail above. In certain embodiments, the unit dosage comprises 1 to 1000 mg, 5 to 250 mg or 10 to 50 mg active ingredient. In particular embodiments, the unit dosages comprise about 1, 5, 10, 25, 50, 100, 125, 250, 500 or 1000 mg active ingredient. Such unit dosages can be prepared according to techniques familiar to those of skill in the art.

Articles of manufacture

[00152] The compounds or pharmaceutically acceptable derivatives can be packaged as articles of manufacture containing packaging material, a compound or pharmaceutically acceptable derivative thereof provided herein, which is used for treatment, prevention or amelioration of one or more symptoms associated with liver cancer, and a label that indicates that the compound or pharmaceutically acceptable derivative thereof is used for treatment, prevention or amelioration of one or more symptoms of liver cancer.

[00153] The articles of manufacture provided herein contain packaging materials. Packaging materials for use in packaging pharmaceutical products are well known to those of skill in the art. See, e.g., U.S. Patent Nos. 5,323,907, 5,052,558 and 5,033,252. Examples of

pharmaceutical packaging materials include, but are not limited to, blister packs, bottles, tubes, inhalers, pumps, bags, vials, containers, syringes, bottles, and any packaging material suitable for a selected formulation and intended mode of administration and treatment. A wide array of formulations of the compounds and compositions provided herein are contemplated.

Kits

[00154] Further provided are kits for use in methods of treatment of liver cancer. The kits can include a caspase inhibitor or composition thereof, and instructions providing information to a health care provider regarding usage for treating or preventing liver cancer. Instructions may be provided in printed form or in the form of an electronic medium such as a CD, or DVD, or in the form of a website address where such instructions may be obtained. A unit dose of an or composition thereof, or a caspase inhibitor or composition thereof, can include a dosage such that when administered to a subject, a therapeutically or prophylactically effective plasma level of the compound or composition can be maintained in the subject for at least 1 day. In some embodiments, the compounds or composition can be included as sterile aqueous pharmaceutical compositions or dry powder (e.g., lyophilized) compositions.

5.8 Evaluation of activity of the compounds

[00155] The biological activity of the compounds can be demonstrated by methods known to one of skill in the art. For example, the evaluation of activity in cell based assays are described by Sharma, S. et al. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nature Reviews Cancer 2010; 10:241-253 and Vecsey-Semjen, B. et al. Novel colon cancer cell lines leading to better understanding of the diversity of respective primary cancers. Nature Oncogene 2002; 21 : 4646-4662, which are incorporated herein by reference in their entirety. Evaluation of activity in animal models of liver cancer are described by Caviglia, J. M., et al. Mouse models of liver cancer. Methods Mol. Biol. 2015; 1267: 165-183, He, L. et al Mouse models of liver cancer: Progress and recommendations. Oncotarget 2015; 6: 23306-22., De Minicis, S et al. Liver carcinogenesis: Rodent models of hepatocellular carcinoma and cholangiocarcinoma. Dig Liver Dis. 2013; 45:450-459 and Li, Y., et al. Hepatocellular carcinoma: Insight from animal models. Nat. Rev. Gastroenterol. Hepatol. 2011; 9: 32-43. which are incorporated herein by reference in their entirety.

[00156] Multiple outcome measures can used for evaluation. One of these is the use of various blood tumor markers, such as, carcinoembryonic antigen (CEA) and carbohydrate antigen 19, (CA-19). These blood tests are used to determine the effect of treatment and determine whether cancer has returned. Radiological imaging techniques are also used to evaluate tumor size and location. These techniques include, computerized tomography scanning, (CT-scans), magnetic resonance imaging (MRI), multidetector computed tomography (MDCT) and positron emission tomography (PET) scans. The extent of liver cancer can be graded by examining liver samples prepared and evaluated microscopically by trained observers.

[00157] The following examples present certain exemplary embodiments and are intended by way of illustration and not by way of limitation.

EXAMPLES

[00158] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how the compounds, compositions, and methods described and claimed herein are made and evaluated, and are intended to be purely exemplary and are not intended to limit the scope of the claimed subject matter. Example 1: In vitro assay

[00159] 5-Fluoruracil (5-FU) was from Sigma Aldrich, Necrostatin-1 was from Enzo Life Sciences. HAT -29 human CRC cell line was obtained from ATCC after cell line authentication utilizing short tandem repeat (STR) profiling. Within four weeks all cell lines were expanded and frozen in aliquots. Cell lines were reauthenticated and regularly tested for contamination as provided by the German Cancer Research Center (DKFZ) Core Facility (Heidelberg). Cells were cultured in RPMI-1640 medium (Biochrom) containing 10% FCS (PAA Laboratories) and 1% penicillin/streptomycin at 5% C0₂ and 37°C.

[00160] HT-29 cells were incubated with 20 μΜ IDN-7314 and/or 20 μΜ Necrostatin (N) for 2 hours prior to treatment with 5-Fluoruracil (5-FU, 50 or 100 mg/ml). After 48 hours, the number of adherent cells was determined via crystal violet assay (RLU = relative light units). Co-treatment with caspase inhibitor IDN-7314 significantly reduced the number of adherent cells. This effect could be abolished by the RIPl-specific kinase inhibitor, necrostatin, the reduced number of cells is due to induction of necrotic cell death.

[00161] Figure 1 demonstrates that IDN-7314 sensitizes colon cancer cells to chemotherapy- induced necrotic cell death.

Example 2 : Xenograft study

[00162] Six-week-old male athymic CD1 nude mice (Charles River) were injected subcutaneously (s.c.) with 1x10^ HT-29 cells in 200 μΐ PBS in the right and left flank using a 27-gauge needle. As soon as tumors were palpable, animals were randomly divided into four groups of treatment (n=8) receiving the following substances: control group (DMSO), 5-FU (40 mg/kg/week), IDN-7314 (120 mg/kg/week) or 5-FU and IDN-7314 (40 and 120 mg/kg/week, respectively). Animals received a first i.p. injection of either DMSO or IDN-7314 (50% DMSO, 150 μΐ), followed by a second injection of either DMSO or 5-FU (4% DMSO, 200 μΐ). Tumor volumes were measured using a micrometer and the ellipsoid formula (length x width x height x ½). After three weeks of treatment animals were sacrificed and formalin-fixed, paraffin embedded tumor sections were used for histological and immunohistochemical analysis.

[00163] Macroscopic and microscopic examination revealed that combination treatment of 5-FU and IDN-7314 for three weeks resulted in synergistically decreased tumor size

accompanied (Figure 2). Histological tumor sections were examined for signs of regression such as sclerosis and necrosis, and quantified using Aperio Image Scope software. As demonstrated in Figure 3, combination treatment of 5-FU and IDN-7314 showed increased signs of tumor regression. Regressive areas as mean percentage of each tumor's size (n=8 ± s.d., Student's t- test, **P < 0.01).

[00164] The forgoing examples illustrate the antitumor activity of a caspase inhibitor in combination with a chemotherapeutic agent used in the treatment of liver cancer. The antitumor efficacy of the combination of the chemotherapeutic agent and the caspase inhibitor is synergistic in reducing tumor size. The combination of a chemotherapeutic agent and a caspase inhibitor is anticipated to be beneficial for the treatment of liver cancer.

[00165] It is understood that the foregoing detailed description and accompanying examples are merely illustrative, and are not to be taken as limitations upon the scope of the subject matter. Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art. Such changes and modifications, including without limitation those relating to the chemical structures, substituents, derivatives, intermediates, syntheses, formulations and/or methods of use provided herein, may be made without departing from the spirit and scope thereof. U.S. patents and publications referenced herein are incorporated by reference.

[00166] The embodiments described above are intended to be merely exemplary, and those skilled in the art will recognize, or will be able to ascertain using no more than routine experimentation, numerous equivalents of specific compounds, materials, and procedures. All such equivalents are considered to be within the scope of the claimed subject matter and are encompassed by the appended claims.

Claims

WHAT IS CLAIMED IS:

1. A method of treating liver cancer, comprising administering, to a subject in need thereof, a therapeutically effective amount of a caspase inhibitor and a chemotherapeutic agent, wherein the chemotherapeutic agent is a compound that shows activity against liver cancer.

2. The method of claim 1, wherein the caspase inhibitor is selected from:

IDN6556, emricasan IDN7314

QVD-OPh

VX-765, belnacasan

or a pharmaceutically acceptable derivative thereof.

3. The method according to claims 1 or 2, wherein the caspase inhibitor is selected from:

IDN6556, emricasan IDN7314

IDN6734 CTS5814

or a pharmaceutically acceptable derivative thereof.

4. The method according to any one of claims 1, 2 or 3, wherein the caspase inhibitor is selected from:

or a pharmaceutically acceptable derivative thereof.

5. The method according to any one of claims 1- 4, wherein the caspase inhibitor is:

IDN7314

or a pharmaceutically acceptable derivative thereof.

6. The method according to claim 1-4, wherein the caspase inhibitor is:

or a pharmaceutically acceptable derivative thereof.

7. The method according to any one of claims 1 or 2, wherein the caspase inhibitor is selected from:

VX-765, belnacasan

harmaceutically acceptable derivative thereof.

8. The method according to claim 7, wherein the caspase inhibitor is:

VX-765, belnacasan

or a pharmaceutically acceptable derivative thereof.

9. The method according to claim 7, wherein the caspase inhibitor is:

or a pharmaceutically acceptable derivative thereof.

10. The method according to claim 7, wherein the caspase inhibitor is:

or a pharmaceutically acceptable derivative thereof.

11. The method of any one of claims 1-10, wherein the chemotherapeutic agent is a chemotherapeutic agent selected from: 5-fluorouracil; doxorubicin; cisplatin; sorafenib;

doxorubicin; cisplatin; mitomycin C; floxuridine; sunitinib; ramucirumab; regorafenib;

lenvatinib; brivanib; tivantinib; linifanib; foretinib; refametinib; selumetinib; erlotinib; lapatinib; carbozantinib; lenalidomide; ABT-263 ( Navitoclax); ABT-199 (Venetoclax); bevacizumab; mapatumumab; nivolumab; pembrolizumab, and ⁹⁰Y loaded on glass or resin microspheres.

12. The method of any one of claims 1-11, wherein the chemotherapeutic agent is 5-fluorouracil.

13. The method of any one of claims 1-12, wherein the caspase inhibitor is:

IDN7314

and the chemotherapeutic agent is 5-fluorouracil.

14. The method of any one of claims 1-13, wherein the patient has been pre-treated with-a therapy for liver cancer.

15. The method of claim 14, wherein the patient has been pre-treated with one or more compounds selected from 5-fluorouracil; doxorubicin; cisplatin; sorafenib; doxorubicin; cisplatin; mitomycin C; floxuridine; sunitinib; ramucirumab; regorafenib; lenvatinib; brivanib; tivantinib; linifanib; foretinib; refametinib; selumetinib; erlotinib; lapatinib; carbozantinib; lenalidomide; ABT-263 ( Navitoclax); ABT-199 (Venetoclax); bevacizumab; mapatumumab; nivolumab; pembrolizumab and ⁹⁰Y loaded on glass or resin microspheres.

16. The method of any one of claims 1-15, wherein the caspase inhibitor and the chemotherapeutic agent are administered sequentially.

17. The method of any one of claims 1-15, wherein the caspase inhibitor and the chemotherapeutic agent are administered simultaneously.

18. The method of any one of claims 1-17 further comprising a surgical resection.

19. The method of claim 18, wherein the surgical resection is performed prior to administering the caspase inhibitor and the chemotherapeutic agent.

20. The method of claim 18, wherein the surgical resection is performed after administering the caspase inhibitor and the chemotherapeutic agent.

21. The method of any one of claims 1-20, further comprising administering a second chemotherapeutic agent, wherein the second chemotherapeutic agent is a compound for the treatment of liver cancer.

22. The method of claims 21, wherein the second chemotherapeutic agent is selected from 5-fluorouracil; doxorubicin; cisplatin; sorafenib; doxorubicin; cisplatin; mitomycin C; floxuridine; sunitinib; ramucirumab; regorafenib; lenvatinib; brivanib; tivantinib; linifanib; foretinib; refametinib; selumetinib; erlotinib; lapatinib; carbozantinib; lenalidomide; ABT-263 ( Navitoclax); ABT-199 (Venetoclax); bevacizumab; mapatumumab; nivolumab; pembrolizumab, and ⁹⁰Y loaded on glass or resin microspheres.

23. The method of claim 21, wherein the second chemotherapeutic agent is administered simultaneously with the caspase inhibitor.

24. The method of claim 21, wherein the second chemotherapeutic agent is administered sequentially prior to or after the caspase inhibitor.

25. The method of any one of claims 1-24, further comprising a radiation therapy.

26. The method of any one of claims 1-25, wherein the liver cancer is caused by a nonalcoholic fatty liver disease, metabolic syndrome, viral disease, alcoholic liver disease, cryptogenic liver cirrhosis, chronic cholestatic liver disease, parasitic infection, ingestion of food-borne toxins or inflammatory bowel disease.

27. The method of any one of claims 1-26, wherein the liver cancer is hepatocellular carcinoma.

28. The method of any one of claims 1-26, wherein the liver cancer is

cholangiocarcinoma.

29. The method of any one of claims 1-28, wherein the liver cancer is refractory to therapy used in the treatment of liver cancer.

30. A kit, comprising a caspase inhibitor, a chemotherapeutic agent for treating liver cancer and a label indicating that the kit is for the treatment or amelioration of one or more symptoms of liver cancer.

31. The kit of claim 30, wherein the caspase inhibitor is in a composition comprising the caspase inhibitor and a pharmaceutically acceptable excipient.

32. The kit of claim 30, wherein the chemotherapeutic agent is in a composition comprising the caspase inhibitor and a pharmaceutically acceptable excipient.

33. The kit of any one of claims 30-38, wherein the caspase inhibitor and the chemotherapeutic agent are in a single composition.

34. The kit of any one of claims 30-38, wherein the caspase inhibitor and the chemotherapeutic agent are in two different compositions.

35. The kit of any one of claims 30-34, wherein the caspase inhibitor is selected from:

IDN6556. emricasan IDN7314

CTS5814

IDN6734

VX166

QVD-OPh

or a pharmaceutically acceptable derivative thereof.

36. The kit according to any one of claims 30-34, wherein the caspase inhibitor is:

or a pharmaceutically acceptable derivative thereof.

37. The kit according to any one of claims 30-34, wherein the caspase inhibitor is:

IDN7314

or a pharmaceutically acceptable derivative thereof.

38. The kit according to any one of claims 30-35, wherein the caspase inhibitor is:

IDN7314

and the chemotherapeutic agent is 5-fluorouracil.

39. A pharmaceutical composition comprising a caspase inhibitor, a

chemotherapeutic agent for treating liver cancer and a pharmaceutically acceptable excipient.

40. The pharmaceutical composition of claim 39, wherein caspase inhibitor is selected from:

IDN6556, emricasan IDN7314

QVD-OPh

41. The pharmaceutical composition according to claims 39 or 40, wherein the caspase inhibitor is:

IDN7314 and the chemotherapeutic agent is 5-fluorouracil.